Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.
Charles MillerHanson KwokPaul HarrowRoser VegaEdward SewardShameer MehtaFarooq RahmanSara McCartneyIoanna ParisiSamuel Hsiang LimEsha SharmaMark A SamaanAaron BancilKlaartje Bel KokAhmed ShalabiEmma L JohnstonDev KatareyNina TaherzadehCharles MurrayMohammed Tauseef SharipMartyn J CarterShiva Thambiah RadhakrishnanSimon PeakeImran KhakooMahmood WahedSebastian PovlsenMehul PatelPatrick DuBoisJemima FinkelClive OnnieStuart BloomPublished in: Frontline gastroenterology (2022)
Compared with second-line anti TNF usage, the VDZ second-line cohort had significantly higher 52-week treatment persistence, UHUC survival, higher colectomy-free survival rates and higher week 52 CFCR. These data suggest that VDZ is an effective biologic in UC as a second-line therapy after anti-TNF exposure. It highlights the effect of biological order on clinically important outcomes.